# **USA Proprietary Name Review Process**

Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Surveillance and Epidemiology (OSE) Division of Medication Errors and Prevention (DMEDP)

# **Proprietary Name Review - Safety**

- Focus of review <u>avoid and prevent</u> medication errors
- Evaluate name and error-prone aspects of:
  - Labels
  - Labeling
  - Packaging
  - Product Design

## **CDER Review of Proprietary Names**

- Review performed by Office of New Drugs (various clinical divisions) and Office Generic Drugs (OND & OGD) in consultation with other CDER offices/divisions
  - Office of Surveillance and Epidemiology/DMEDP
  - Office of Medical Policy/DDMAC
  - Joint review with CBER in some cases
  - Final Decision rests with OND & OGD

## **Pre-Marketing Review Process**

- Name Analysis : Multi-factorial process
- Labeling and Packaging Analysis
- Overall Risk Evaluation
- Written Recommendation Provided to Division

# **CDER Proprietary Name Review**

- Name Analysis Begins:
  - End of Phase II or New Drug Application (NDA) or Biologics License Application (BLA) or Abbreviated New Drug Application (generics) (ANDA)
  - Sponsors submit 2 names
    - Primary (1<sup>st</sup> choice)
    - Secondary (2<sup>nd</sup> choice)
- Name Reviewed:
  - Investigational New Drug (IND) and/or NDA/BLA/ANDA & 90 days prior to approval
- Product Characteristics must be known for analysis to BEGIN

## **Product Characteristics**

Any or all characteristics of product can increase or decrease risk, and MUST be considered in risk assessment of name:

- Drug Name (Generic & Brand name, Suffix ,etc)
- Dose, strength(s), dose form
- Packaging
- Physical attributes
- Route
- Frequency of administration
- Instructions for use
- Storage requirements
- Indications, patient population
- Likely care environment
- Contraindications, etc.

# **Contributing Factors**

- Overlapping strengths or dosing intervals
- Same patient and prescriber populations
- Identical formulations
- Similar indications for use
- Similar storage location
- Other

### **Pre-Marketing Multi Faceted Review**

#### Expert Panel Review


- Medication Error Safety Evaluators + Division
  Drug Marketing Advertising and Communication (DDMAC)
- Meet weekly
- Rely on clinical, regulatory and professional experiences

#### Handwritten and Verbal Analysis

- Simulated drug name studies are sent to  $\cong$  120 FDA volunteers
- The results provide a valuable tool for predicting potential confusion with marketed drugs

### **Pre-Marketing Multi Faceted Review**

- Literature, textbook, and computer database searches
  T&T Sagis, POCA, Drug Reference texts
- USAN (INN) Stem List
- Clinical experience of Safety Evaluators
- Lessons Learned from Post-marketing Experience
- Labeling and Packaging Analysis
  - Applying principals of Human Factors
- FMEA
  - Identifies failure causes
    - Where and how might confusion occur in the medication use system
    - Everyone in the medication use process considered
  - Determines failure effects
    - Can the confusion conceivably result in error in the usual practice



### Must Consider Medication Use System

- Prescriber population
- Prescribing & Ordering
- Clinical setting
- Purchasing
- Storage
- Delivery
- Administration

- Monitoring
- Therapy adjustments
- Duration of therapy
- Reordering
- Disposal
- External influences on the process

Considerations are Dependent on Type of Submission

- New Molecular Entity
- Product Line Extension
- Different proprietary names for the same active ingredient
  - Potential for confusion, overdosing, concomitant administration, allergies, hypersensitivity reactions
  - Generally discouraged
- Same proprietary name for different active ingredient
  - "Family" trade names for OTC products (e.g., Dulcolax, Robitussin, Maalox)
  - Foreign trade name (e.g., Dilacor Diltiazem U.S. and Digoxin in Serbia)
- Each type offers unique opportunities for error

# **DMEDP** Philosophy

CDER's Threshold for Name and Risk Assessment is set low because it is a predictable and preventable source that can often be *identified* and *remedied* prior to approval to avoid patient harm.

# **DMEDP** Philosophy

- Post-approval efforts at reducing errors should be reserved for those cases in which *errors could not be predicted* prior to approval.
- Prevention of error is the goal.
- Reaction after a predictable error has already occurred is not sufficient.

## Summary

- Drug names, labels, and packaging are major contributors to medication error
- Risk assessment includes product characteristics (not just names)
- Risk for error is determined by both drug product characteristics and the care system processes where drugs are used
- The predictable nature of errors provides opportunity for better name and product design to enhance safety